Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
Jinhua Ren,
QiaoXian Lin,
Qi Chen,
Jingjing Xu,
Dabin Chen,
Renli Chen,
Kangni Lin,
Haojie Zhu,
Chenjing Ye,
Xiaofeng Luo,
Shaozhen Chen,
Hui Kong,
Qiong Lin,
Nan Li,
Xu Lin,
Zhizhe Chen,
Jianda Hu,
Ting Yang
Affiliations
Jinhua Ren
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
QiaoXian Lin
Department of Hematology, The First Affiliated Hospital of Fujian Medical University, 20 Cha Zhong Road, 350005, Fuzhou, Fujian, P. R. China
Qi Chen
Department of Hematology, Ningde municipal hospital of Ningde normal university, 13 Mindong Dong Road, 352100, Ningde, Fujian, P. R. China
Jingjing Xu
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Dabin Chen
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Renli Chen
Department of Hematology, Ningde municipal hospital of Ningde normal university, 13 Mindong Dong Road, 352100, Ningde, Fujian, P. R. China
Kangni Lin
Department of Critical Care Medicine, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, 420 Fuma Road, Fuzhou, Fujian, P. R. China
Haojie Zhu
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Chenjing Ye
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Xiaofeng Luo
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Shaozhen Chen
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Hui Kong
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Qiong Lin
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Nan Li
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Xu Lin
Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou 350122, China
Zhizhe Chen
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China
Jianda Hu
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China; Corresponding author
Ting Yang
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Road, 350001, Fuzhou, Fujian, P. R. China; Corresponding author
Summary: Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA（87.5%） and HBsAg（11.1%%）cleared in HBsAg+ patients. All HBsAg- patients acquired HBsAb immediately. Nevertheless, HBsAb titers subsequently declined, and 39/67 (58.2%) patients lost HBsAb during follow-up. The 5-year overall survival (OS) was better in patients who lost HBsAb. Multivariate analysis showed that the independent risk factors for OS were lack of cytomegalovirus (CMV) clearance, acute graft-versus-host disease (aGVHD), and no HBsAb loss. Overall, adoptive immune transfer offers anti-HBV protection to patients without HBsAb, as they acquire HBsAb and clear HBV-DNA and HBsAg, while HBsAb loss after allo-HSCT predicts better survival.
